RemeGen Co. Ltd. Class H (HK:9995) has released an update.
RemeGen Co., Ltd. is celebrating the NMPA’s full approval of its autoimmune treatment, telitacicept, for rheumatoid arthritis patients unresponsive to standard methotrexate therapy. The approval follows promising Phase III clinical trial results, showing significant improvements in patient response rates, joint structure preservation, and reduction in inflammation. Telitacicept, a novel fusion protein targeting key B-cell signaling molecules, is also being tested for other autoimmune diseases, addressing critical unmet medical needs.
For further insights into HK:9995 stock, check out TipRanks’ Stock Analysis page.